Minerva Neurosciences (NERV)
NASDAQ:NERV
Want to see NERV full AI Analyst Report?
NERV Stock Chart & Stats
$6.29
-$0.09(-3.83%)
At close: 4:00 PM EST
$6.29
-$0.09(-3.83%)
Day’s Range― - ―
52-Week Range$1.30 - $12.46
Previous CloseN/A
Volume1.19K
Average Volume (3M)465.60K
Market Cap
$267.44M
Enterprise Value$26.65M
Total Cash (Recent Filing)$82.30M
Total Debt (Recent Filing)$64.96M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding43,274,400
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.79K
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$10.50Price Target Upside66.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.74
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing And Program FundingAnalyst notes the company secured fresh financing and a registration shelf that provide flexibility to fund the program and support continued study progress.
KOL Support And Unmet NeedKOL feedback supports Phase 3 plans to pursue the first approved treatment for negative symptoms of schizophrenia, highlighting a significant unmet medical need and potential commercial opportunity.
Regulatory AlignmentAnalyst cites alignment with the FDA on the confirmatory Phase 3 design, supporting a pathway for potential approval of the drug as monotherapy for patients with stable positive symptoms and impaired negative symptoms.
Bears Say
Comparative Efficacy UncertaintyPlanned comparison to standard antipsychotic treatment will be descriptive rather than a formal non-inferiority test, leaving uncertainty about long-term comparative efficacy and safety.
Pivotal Endpoint RiskPerformance on the personal and social functioning scale is likely to be pivotal given prior regulatory concerns, creating trial risk if results are not clearly positive.
Prior Trial Failure And Execution RiskA prior Phase 3 study failed to meet its primary endpoint due to patient quality and variability issues, introducing execution risk for the ongoing program.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.30 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $267.44M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is May 06, 2026 which is in 19 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Mar 11, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.302 by -$0.338.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.13.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 43,274,400 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.302. Following the earnings report the stock price went down -8.06%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Minerva Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (66.93% Upside)
$10.50 (66.93% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.48%
12-Months-Change
Fundamentals
Return on Equity
506.72%
Trailing 12-Months
Asset Growth
163.76%
Trailing 12-Months
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
NERV Stock 12 Month Forecast
Average Price Target
$10.50
▲(66.93% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
―
Aspire Biopharma Holdings
―
Ownership Overview
1.10%
Insiders
3.39% Mutual Funds
39.13% Other Institutional Investors
55.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---